Climb Bio (CLYM) Investor Presentation summary

Mission and strategy

• Focused on developing disease-modifying monoclonal antibody (mAb) therapeutics for immune-mediated diseases, especially those impacting kidney health, with significant commercial potential.

• Leveraging clinically validated B cell targets and proven mAb modalities for indications with established regulatory pathways.

• Aims to deliver transformative medicines for patients with high unmet needs in B cell-mediated and autoimmune diseases.

Pipeline and clinical development

• Five clinical studies underway, with initial data readouts anticipated from all ongoing trials in 2026.

• Budoprutug (anti-CD19 mAb) in development for primary membranous nephropathy (PMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE); CLYM116 (anti-APRIL mAb) in development for IgA nephropathy (IgAN).

• Budoprutug offers both IV and subcutaneous (SC) formulations, with SC Phase 1 trial in healthy volunteers ongoing.

• CLYM116 Phase 1 trial in healthy volunteers is ongoing, with initial data expected mid-2026.

Clinical results and differentiation

• Budoprutug demonstrated rapid, deep, and durable B cell depletion and high rates of serologic and clinical remission in PMN Phase 1b study.

• All patients in the primary analysis set achieved complete or partial clinical remission by Week 48, with long-term control of proteinuria observed.

• Budoprutug was generally well tolerated, with no dose-limiting toxicities or discontinuations due to adverse events.

• CLYM116 preclinical and NHP data show deep and durable IgA suppression, long half-life, and favorable safety profile.